# LAM561 With RT and TMZ for Adults With Glioblastoma

Source: https://onco.cc/trials/nct04250922/  
OnCo record `nct04250922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing LAM561 in glioma & glioblastoma, active and no longer recruiting.

## Summary

LAM561 With RT and TMZ for Adults With Glioblastoma is a phase 2/3 interventional study registered as NCT04250922, led by Laminar Pharmaceuticals with Laboratory of America, Northern Institute for Cancer Research, Newcastle and Theradis pharma, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment. Planned enrolment is 144 participants (actual). The study started in 2019-12-01 and primary completion is expected in 2026-01-15. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: CLINGLIO
- Tags: ctgov-ingest
- Registry id: NCT04250922
- Phase: 2/3
- Setting: A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment
- Sponsor: Laminar Pharmaceuticals
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT04250922: https://clinicaltrials.gov/study/NCT04250922

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [LAM561](https://onco.cc/drugs/lam561/)
- companies: [Laminar Pharmaceuticals](https://onco.cc/companies/laminar-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04250922.json